Abvc Biopharma (ABVC) Intangibles (2011 - 2026)
Abvc Biopharma's (ABVC) quarterly Intangibles came in at $3.5 million in Q2 2026, up 5318.46% quarter-over-quarter from $64594.0 in Q4 2015.
Powered by 
Analysis
Abvc Biopharma (ABVC) Intangibles (2011 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has reported Intangibles for 4 consecutive years, with $3.5 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Intangibles changed N/A year-over-year to $3.5 million; the trailing twelve-month figure through Jun 2026 stood at $3.5 million (changed N/A YoY), and the FY2015 full-year result was $64594.0, changed N/A from the prior year.
- Intangibles climbed to $3.5 million in Q2 2026 per ABVC's latest filing, from $64594.0 in the prior quarter.
- Across five years, Intangibles topped out at $3.5 million in Q2 2026 and bottomed at $3.5 million in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 20.49 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 14.03 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 412.80 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 1.31 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 266.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 13.52 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Abvc Biopharma | 25.56 Mn | 25.56 Mn | - | 3.50 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.50 Mn |
| Dec 31, 2015 | 64,594.00 |
| Sep 30, 2015 | 64,594.00 |
| Jun 30, 2012 | 202,630.00 |
| Sep 30, 2011 | 198,915.00 |